ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO055

AKI and Remission of Proteinuria in Adult-Onset Minimal Change Disease: A Multicenter Retrospective Cohort Study

Session Information

  • AKI Clinical: Predictors
    November 03, 2017 | Location: Hall H, Morial Convention Center
    Abstract Time: 10:00 AM - 10:00 AM

Category: Acute Kidney Injury

  • 003 AKI: Clinical and Translational


  • Shinzawa, Maki, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
  • Nagasawa, Yasuyuki, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
  • Yamamoto, Ryohei, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
  • Yamauchi, Atsushi, Osaka Rosai Hospital, Sakai-city, Japan
  • Fukunaga, Megumu, Toyonaka Municipal Hospital, Toyonaka, Japan
  • Hayashi, Terumasa, Osaka General Medical Center, Osaka, Japan
  • Izumi, Masaaki, Kansai Rosai Hospital, Amagasaki, Hyogo, Japan
  • Isaka, Yoshitaka, Osaka University Graduate School of Medicine, Suita, Osaka, Japan

Group or Team Name


Acute kidney injury (AKI) is common (20% to 50%) in adult-onset minimal change disease (MCD). However, its effect on remission of proteinuria is unknown.


Design: a multicenter retrospective cohort study, the STudy of Outcomes and Practice patterns of Minimal-Change Disease (STOP-MCD).
Patients: 117 nephrotic patients aged ≥15 years with histological diagnosis of primary MCD between 2000 and 2009 in 5 hospitals in Japan.
Outcome: First remission of proteinuria defined as urinary protein < 0.3 g/day, urinary protein / creatinine ratio < 0.3, and/or negative/trace result of dipstick test.
Exposure: AKI defined as ≥0.3mg/dL of an increase of creatinine (Cre) at initiating immunosuppressive therapy.
Statistics: Multivariable Cox proportional hazards (CPH) model.


Baseline characteristics at initiating of immunosuppressive therapy.of AKI group (n=29) and non-AKI group (n=88) were as follows; age, median 53 [interquantile range 28, 63] vs. 37 [22, 58] yr (P=0.135); male, 66 vs. 61 % (P=0.689); Cre, 1.6 [1.3, 2.0] vs. 0.8 [0.7, 0.9] mg/dL (P<0.001); serum albumin, mean 1.8 ± SD 0.6 vs. 1.8 ± 0.6 g/L (P=0.950); urinary protein, 11.6 [7.9, 14.7] vs. 7.2 [3.3, 14.4]) g/day (P=0.021); initial dose of prednisolone, 0.7 ± 0.1vs. 0.7 ± 0.2 mg/Kg (P=0.449).
During 4.2 [2.2-7.2] year of the observational period, all patient achieved remission.
Maximum Cre after initial treatment was 2.5 [2.0-3.6] mg./dL in AKI group and 0.9 [0.8-1.2] mg/dL in non-AKI group.
Remission was delayed in AKI group (27 [19, 45] vs. 12 [9, 24] day, P=0.002) (Figure). AKI was identified as a significant predictor of remission in the multivariable CPH model (AKI vs. non-AKI, hazard ratio 0.48 [95% confidence interval 0.29-0.79, P=0.004]).


AKI before immunosuppressive therapy delayed remission of proteinuria in adult-onset MCD.


  • NIDDK Support